Pain Therapeutics (PTIE) Getting Somewhat Positive News Coverage, Study Finds

Press coverage about Pain Therapeutics (NASDAQ:PTIE) has been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pain Therapeutics earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 47.4521518922918 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:

Several research analysts recently weighed in on the stock. Zacks Investment Research cut shares of Pain Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 19th. Gabelli cut shares of Pain Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, July 17th.

Pain Therapeutics (NASDAQ:PTIE) traded down $0.03 on Tuesday, reaching $3.62. 162,135 shares of the company’s stock were exchanged, compared to its average volume of 764,023. Pain Therapeutics has a 12-month low of $3.10 and a 12-month high of $9.31.

Pain Therapeutics (NASDAQ:PTIE) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.40) EPS for the quarter. equities analysts forecast that Pain Therapeutics will post -2.2 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at

Pain Therapeutics Company Profile

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Insider Buying and Selling by Quarter for Pain Therapeutics (NASDAQ:PTIE)

Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply